Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -5.26% Market Closed
Market Cap: 189.3m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Arovella Therapeutics Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arovella Therapeutics Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
MYX
NEU
BOT
PBP
VLS

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Arovella Therapeutics Ltd
ASX:ALA
Cash & Cash Equivalents
AU$12.7m
CAGR 3-Years
24%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash & Cash Equivalents
AU$110.1m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash & Cash Equivalents
AU$2.6m
CAGR 3-Years
-48%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash & Cash Equivalents
AU$79.3m
CAGR 3-Years
54%
CAGR 5-Years
76%
CAGR 10-Years
41%
Probiotec Ltd
ASX:PBP
Cash & Cash Equivalents
AU$12.8m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
34%
Vita Life Sciences Ltd
ASX:VLS
Cash & Cash Equivalents
AU$27.7m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
11%

See Also

What is Arovella Therapeutics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
12.7m AUD

Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Cash & Cash Equivalents amounts to 12.7m AUD.

What is Arovella Therapeutics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
24%

Over the last year, the Cash & Cash Equivalents growth was 146%. The average annual Cash & Cash Equivalents growth rates for Arovella Therapeutics Ltd have been 24% over the past three years , 24% over the past five years .

Back to Top